Pergamum announces last visit of last patient in a Phase I/II trial of a potential new treatment for hard-to-heal wounds
STOCKHOLM – April 19, 2013. Pergamum AB announced today that the company has reached last-patient-last-visit (LPLV) in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.
Non-healing wounds are a sizable burden for the individual patient and for the health care system. Today, there are more than 15 million patients globally, and virtually no medical progress has been made over the last few decades in regard to pharmacological treatments.
"LL-37 is a therapeutic peptide which contributes to enhanced healing of chronic wounds through its biological role in the human host defense system", said Jonas Ekblom, CEO of Pergamum AB. "This clinical trial will allow us to evaluate a promising new treatment aimed for the segment of advanced wound care products.”
In this double blind multicenter study, 34 patients with venous leg ulcers have been randomized to receive either placebo or one of three different doses of LL-37. The primary objective of the trial is to assess the safety and tolerability of Pergamum’s proprietary formulation of the therapeutic peptide
LL-37. The trial will be concluded in 2013. The principal investigator is Dr. Ola Rollman, associate professor at the Department of Medicine at Uppsala University, Sweden.
"We look forward to evaluate the top line-data from the study, which we anticipate will be presented in the third quarter”, said Torbjörn Bjerke, CEO of Karolinska Development AB and Chairman of the Board of Pergamum.
For further information, please contact:
Jonas Ekblom, President and CEO, Pergamum AB
Phone: +46 (0)70 551 6660, e-mail: jonas.ekblom@pergamum.com
Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com
TO THE EDITORS
About Pergamum
Pergamum is a biopharmaceutical company specialized in the development of therapeutic peptides for local application in infections and wounds. The company’s vision is to develop a portfolio of unique development programs representing high medical value that ultimately, through global partnerships, will result in first-in-class and first-in-category products. The current development pipeline includes several therapeutic peptides of which three programs are in clinical development, with potential for use in several medical applications. Please visit our web site: www.pergamum.com.
About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 15 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.